Trding - this is a very , very good post and IMO

Trding - this is a very , very good post and IMO very accurate.

There might be some patients who's cancers will be cured , but majority will go from deadly disease , into chronic , like in some other diseases egz diabetes .

Most of CCR5 inhibitors do have many severe side effects , some couldn't be approved for this reason by FDA , so in the past , plans were to use them here or there where things getting worse.

I don't think that many predicted CCR5 inhibitor like Leronlimab , so far with very good efficacy and so far, for so many years and patients , without one serious side effect.

Its rarity in medicine !!!!

So IMO in majority of patients with this very deadly cancers and CCR5 positive , Leronlimab will be use forever , or at least with very close monitoring of CTC results.

Of course if our clinical trials will be positive !!! ....So I am waiting impatiently for our study..

And as Dr Pestell commented during one of our CC , with Leronlimab other chemotherapy works about 250% better , so hopefully patients will need lower dose of it .

We will learn a lot during our TNBC study..